Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : Announces Reintroduction of Generic Depo-Provera® in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 06:01pm CET

By a News Reporter-Staff News Editor at Clinical Trials Week -- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy (see also Pharmaceutical Companies).

"This reintroduction brings an additional product to a market that was previously lacking in options," said Dr. Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D. "In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities."

Teva has been committed to strengthening its generic injectable business globally, by making continued investment in newer, higher-value generic injectable products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Medroxyprogesterone acetate injectable suspension, USP 150 mg/mL had annual sales of approximately $211 million in the United States, according to IMS data as of July 2017. About Medroxyprogesterone Acetate Injectable Suspension, USP Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term. Important Safety InformationWomen who use medroxyprogesterone acetate injectable suspension may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible. Medroxyprogesterone acetate injectable suspension should not be used as a long-term birth control method (i.e., longer than 2 years) unless other birth control methods are considered inadequate. The use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: known or suspected pregnancy or as a diagnostic test for pregnancy; active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease; known or suspected malignancy of breast; known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients; significant liver disease; or undiagnosed vaginal bleeding.

Studies have shown an increased risk of breast cancer in women using medroxyprogesterone acetate injectable suspension. Serious thrombotic events; anaphylaxis and anaphylactoid reaction; injection site reactions; convulsions; weight gain; and decreased glucose tolerance have been reported with the use of medroxyprogesterone acetate injectable suspension.

In clinical trials the most common adverse reactions (incidence > 5%) were: menstrual irregularities (bleeding or spotting), abdominal pain/discomfort, dizziness, headache, nervousness, and decreased libido. Medroxyprogesterone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Keywords for this news article include: Antineoplastics, Pharmaceutical Companies, Teva Pharmaceutical Industries Ltd, Oncology, Progestins, Sex Hormones, Bone Research, Breast Cancer, Contraceptives, Drugs and Therapies, Risk and Prevention, Breast Ductal Carcinoma, Medroxyprogesterone Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17 TEVA PHARMACEUTICAL INDUSTRIES : FDA approves Teva leukemia treatment
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX Injecti..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX (arseni..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Embattled Teva fined NIS 75m. for bribing forei..
01/15 TEVA PHARMACEUTICAL INDUSTRIES : settles graft case with Israeli authorities
01/15 TEVA PHARMACEUTICAL INDUSTRIES : agrees future of Abic Netanya with workers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : corruption settlement doesn't cover co officers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX® (arsen..
01/14 TEVA PHARMACEUTICAL INDUSTRIES : Moody's cuts Teva debt to junk status
More news
News from SeekingAlpha
05:24a The Re-Balancing Act
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/16 FDA OKs Teva's Trisenox for certain type of APL
01/15 UPDATE : Neos Therapeutics Seems To Be Capitalizing On Pfizer's Decisions
01/13 THE PASSIVE DGI CORE PORTFOLIO : 2017 End-Of-Year Review
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,47x
EV / Sales 2018 2,39x
Capitalization 21 478 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 23,3 $
Spread / Average Target 11%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287